As patient specific, autologous cell therapies are advancing through clinical trials and are moving quickly toward commercialization, there continues to be a need for robust, closed, automated and scalable manufacturing solutions that can accommodate many patient samples, simultaneously. What will be required is a means to process patient material in a fashion which maximizes the efficiency of the processing workflow while meeting safety, quality and regulatory requirements. Any production approach should retain the fundamental principles of preventing contamination, patient sample mixing, loss of identity, and other events which may compromise the physical properties and integrity of the patient sample and/or final product.